Slide 1: Oncology Overview ASCO 2020
Merck Oncology Overview ASCO 2020
Slide 2: Forward-looking statement
Forward-looking statement This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current bel
Slide 3: Executing on a broad oncology strategy to improve outcomes for cancer patients
We are executing on a broad oncology strategy to improve outcomes for cancer patients globally Further establish Broadly explore Advance pipeline Identify patients KEYTRUDA as combinations to and pursue strategic most likely to foundational treatment reach more patients collaborations benefit using
Slide 4: KEYTRUDA has demonstrated activity in more than 30 types of cancer
KEYTRUDA has now demonstrated activity in more than 30 different types of cancer defined by site of origin, histology, or genetic markers Melanoma1 NSCLC2 H&N3 Urothelial4 TNBC5 Gastric6 cHL7 NHL PMBCL8 Mesothelioma9 100 100 100 100 100 100 100 100 100 0 0 0 0 0 0 0 0 0 -100 -100 -100 -100 -100 -100
Slide 5: KEYTRUDA improves overall survival in Phase 3 studies across malignancies
KEYTRUDA monotherapy and in combination improves overall survival in Phase 3 studies across a broad range of malignancies KEYNOTE-006 KEYNOTE-040 KEYNOTE-181 KEYNOTE-240 KEYNOTE-119 KEYNOTE-045 Pembro vs Ipi Pembro vs SOC Pembro vs Chemo Pembro vs Placebo Pembro vs Chemo Pembro vs Chemo Ipi-Naive Me
Slide 6: Comprehensive KEYTRUDA development program
Comprehensive KEYTRUDA development program >800 Combination trials >110 Trials in >1,200 adjuvant / neoadjuvant Ongoing and earlier lines clinical trials >90 Registrational trials under way 6
Slide 7: ASCO 2020: Continued flow of data from deep & diverse oncology portfolio
ASCO 2020: Continued flow of data from deep & diverse oncology portfolio Presenting new Demonstrating Progressing novel KEYTRUDA data KEYTRUDA’s long-term mechanisms survival benefits New Phase 3 data for KEYTRUDA Long-term survival data for New Phase 2 data from our oral HIF- in TNBC, MSI-H CRC and
Slide 8: KEYNOTE-355: Improved efficacy in TNBC development program
KEYNOTE-355: Improved efficacy and supportive of overall TNBC development program Progression-Free Survival: PD-L1 CPS > 10 KEYTRUDA plus chemo reduced the risk of disease progression or death by 35% vs. chemo for certain TNBC patients (HR = 0.65 [95% CI, 0.49-0.86], p=0.0012) Trial continues for OS
Slide 9: KEYNOTE-177: Single-agent KEYTRUDA may become new standard of care in 1L MSI-H mCRC
KEYNOTE-177: Single-agent KEYTRUDA may become new standard of care in 1L MSI-H mCRC patients KEYTRUDA monotherapy 100 90 significantly reduced risk of 80 12-mo rate disease progression or 70 60 55% 37% 24-mo rate 48% Median (95% CI) 16.5 mo (5.4-32.4) death by 40% and more PFS, % 19% than doubled me
Slide 10: KEYNOTE-204: Displacing standard of care in 2L+ relapsed refractory cHL
KEYNOTE-204: Displacing standard of care in 2L+ relapsed refractory classic Hodgkin’s lymphoma KEYTRUDA monotherapy showed statistically significant and clinically meaningful improvement in PFS versus BV in R/R cHL (HR = 0.65 [95% CI, 0.48-0.88], p=0.00271) Trial continues for OS Data cutoff: Jan. 1
Slide 11: Long-term follow-up data confirm durable overall survival benefits with KEYTRUDA
Long-term follow-up data confirm durable overall survival benefits with KEYTRUDA used in combination or as an adjuvant following surgery +XX% YOY NSCLC RCC Melanoma In the final analysis of KEYNOTE-189, An updated analysis from KEYNOTE-426 In a 3-yr follow-up on KEYNOTE-054, KEYTRUDA in combination
Slide 12: MK-6482: First-time data shows promising response rate in VHL-associated kidney cancer
MK-6482: First-time data shows promising overall response rate in Von-Hippel Lindau (VHL)-associated kidney cancer patients VHL disease is a multi-system disease with most patients Areas of the Body Affected by von Hippel-Lindau Disease having several different tumors Data demonstrates the therapeut
Slide 13: KEYTRUDA broad adjuvant program with 20 registrational studies ongoing
KEYTRUDA is being explored in a broad adjuvant program with 20 registrational studies ongoing 2018 2019 2020 2021 2022 2023 2024 2025 2026+ Adjuvant TNBC cSCC Locally HNSCC Adjuvant Adjuvant Gastric & NSCLC Neo/adjuvant TNBC Adjuvant Melanoma Neoadjuvant / Advanced (KEYNOTE-412) Melanoma Esophageal
Slide 14: Extensive KEYTRUDA+LYNPARZA combination (KEYLYNK) and LYNPARZA monotherapy programs
Extensive KEYTRUDA+LYNPARZA combination (KEYLYNK) and LYNPARZA monotherapy programs Tumor • mCRPC, All Comers (KEYLYNK-010) Tumor Agnostic agnostic • 1L, nonBRCA, KEYTRUDA combo (KEYLYNK-001) • mCRPC, HRRm (PROfound) - Approved • 1L Maintenance BRCA+ (SOLO-1) - Approved • mCRPC, All Comers Combo + A
Slide 15: Extensive KEYTRUDA+LENVIMA combination (LEAP) and LENVIMA monotherapy programs
Extensive KEYTRUDA+LENVIMA combination (LEAP) and LENVIMA monotherapy programs • 1L PD-L1+ HNSCC (LEAP- 010) • 1L NSQ Combo with KEYTRUDA and Chemo (LEAP-006) Basket trial • 1L PD-L1+ NSCLC (LEAP-007) Head & neck • 2L NSQ (LEAP-008) cancer Urothelial • TNBC • 1L EC (LEAP-001) cancer • Gastric • 2L E
Slide 16: Early oncology pipeline includes more than 20 investigational immuno-therapeutic candidates
Early oncology pipeline* includes more than 20 investigational immuno-therapeutic candidates – including novel combinations with KEYTRUDA Pre-Clinical Phase 1 Phase 1/2 Phase 2 Molecules designed to RIG-I receptor CD-27 agonist stimulate immune system Immune functions, such as enhancing (MK-4621) (M
Slide 17: Collaborations, licensing agreements, and acquisitions to benefit cancer patients
We have pursued collaborations, licensing agreements, and acquisitions that will increase our ability to provide benefit to cancer patients Acquisition Development Program Development Stage Development of novel small molecule therapeutic candidates targeting Phase 3 in RCC HIF-2α for the treatment o
Slide 18: Creating long-term value for patients, employees and shareholders
Creating long-term value for patients, employees and shareholders Next 5 Years 5-10 Years 10+ Years Strong execution driving Rich pipeline addressing Revitalized discovery efforts and sustainable revenue growth, areas of high unmet need to increased expertise in biology to meaningful margin expansio
Slide 19: Q&A
Q&A To ask a question on the operator-assisted audio line, press *1. Note: be sure to mute your computer speakers if you are listening to the audio webcast. 19